CUE · Cue Biopharma, Inc. · Investor Relations

Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflection Strengthened the leadership team

Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergy BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement

Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma,

Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Enhanced the company’s portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D.

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health -led Phase 2 study in chronic spontaneous